{"status":"success","data":{"title":"NSAIDs and Upper GI Bleed","slug":"nsaid-gi-bleed","tags":["Ibuprofen","Diclofenac","Meloxicam","Indomethacin","Ketoprofen","Naproxen","Piroxicam","Ketorolac","Celecoxib","Aceclofenac","Rofecoxib"],"collection":["Gastroenterology","Pharmacology"],"content":"<h1 id=\"nsaids-and-upper-gi-bleed\">NSAIDs and Upper GI Bleed</h1>\n<ul>\n<li>Stomach and platelets have much more COX-1 receptors than COX-2 receptors.</li>\n<li>Below are statistics from systematic review on NSAIDs and upper GI complications(bleeding, perforation)</li>\n</ul>\n<p><strong>Ketorolac pearls</strong></p>\n<ul>\n<li>Has the highest upper GI complication RR (14.54)</li>\n<li>Before giving, first check that patients don&#39;t have a history of a GI bleed or peptic ulcer</li>\n</ul>\n<table>\n<thead>\n<tr>\n<th></th>\n<th></th>\n<th></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td><strong>NSAID medication</strong></td>\n<td><strong>Relative risk of complication</strong></td>\n<td><strong>[95 % CI]</strong></td>\n</tr>\n<tr>\n<td>COX-1 Inhibitors (all)</td>\n<td>4.5</td>\n<td>[3.82-5.31]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Ibuprofen</span></td>\n<td>2.69</td>\n<td>[2.17-3.33]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Diclofenac</span>*</td>\n<td>3.98</td>\n<td>[3.36-4.72]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Meloxicam</span>*</td>\n<td>4.15</td>\n<td>[2.59-6.64]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Indomethacin</span>*</td>\n<td>5.40</td>\n<td>[4.16-7.00]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Ketoprofen</span>*</td>\n<td>5.57</td>\n<td>[3.94-7.87]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Naproxen</span>*</td>\n<td>5.63</td>\n<td>[3.83-8.28]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Piroxicam</span></td>\n<td>9.94</td>\n<td>[5.99-16.50]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Ketorolac</span></td>\n<td>14.54</td>\n<td>[5.87-36.04]</td>\n</tr>\n<tr>\n<td>COX-2 Inhibitors (all)</td>\n<td>1.88</td>\n<td>[0.96-3.71]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Celecoxib</span></td>\n<td>1.42</td>\n<td>[0.85-2.37]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Aceclofenac</span></td>\n<td>1.44</td>\n<td>[0.65-3.2]</td>\n</tr>\n<tr>\n<td>- <span class=\"drug\">Rofecoxib</span></td>\n<td>2.12</td>\n<td>[1.59-2.84]</td>\n</tr>\n</tbody>\n</table>\n<p><em>\\</em> = Estimated relative risk*</p>\n<h2 id=\"risk-factors-for-upper-gi-complication\">Risk Factors for Upper GI Complication</h2>\n<ol>\n<li><span class=\"aglmd-moreinfo ui-moreinfo\" data-iid=\"53aa2488d35d3ae92e001f47\">Longer drug half-life</span></li>\n<li>Slow-release formulation</li>\n<li><span class=\"aglmd-moreinfo ui-moreinfo\" data-iid=\"53aa2488d35d3ae92e001f48\">Dual inhibition of COX-1 and COX-2 isoenzymes</span> </li>\n</ol>\n<p>Relative risk is greatest when first starting medication (&lt; 30 days)</p>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=20178131\">Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6):1592-601</a></li>\n</ul>\n"}}